Wang Jin-Ming, Wang Ying, Zhu Zhong-Sheng, Zhang Mei-Chun, Zou Yi, Li Jian-Jun, Li Ming-Jiang, Jiang Xue-Jun, Li Xiao-Yan
Department of Cardiology, Renmin Hospital, Wuhan University School of Medicine, Wuhan 430060, People's Republic of China.
Life Sci. 2004 Jun 11;75(4):407-20. doi: 10.1016/j.lfs.2003.10.040.
To compare diverse effects of angiotensin II type 1 receptor antagonists (irbesartan) and angiotensin converting enzyme inhibitors (imidapril) on left ventricular remodeling in spontaneously hypertensive rats (SHR). Thirty male SHR were randomly divided into three groups: SHR-IR (treated with irbesartan, 50 mg/kg), SHR-IM (imidapril, 3 mg/kg), SHR-C (placebo). Ten male Wistar Kyoto rats (WKY) treated with placebo acted as the control. All treatments were administered once daily from 14 to 27 weeks of age. Imidapril and irbesartan have the similar inhibitor effects on blood pressure and left ventricular mass indexes in SHR. Despite both drugs suppressed ERK-1 protein expression, decreased cardiomyocytes apoptosis index, blocked collagen type I deposition, reduced TGF-beta(1) gene expression in SHR, imidapril elicits a stronger inhibitory effect. Irbesartan had little effect on MKP-1 protein expression, but imidapril decreased it significantly. As a result, the ERK-1/MKP-1 ratio in SHR-IR was significantly greater than that in SHR-IM (P < 0.05). These results suggest that the balance between MKP-1 and ERKs in myocardial tissue is important for cardiac cell proliferation and growth. They also indicate that the similar efficacy of antihypertensive treatment in reducing blood pressure does not predict the similar capacity to control the individual facet of left ventricular remodeling. Irbesartan is more effective in regressing the homeostasis between ERK-1 and MKP-1, however imidapril is superior in suppressing apoptosis and collagen synthesis in cardiac tissue.
比较血管紧张素II 1型受体拮抗剂(厄贝沙坦)和血管紧张素转换酶抑制剂(咪达普利)对自发性高血压大鼠(SHR)左心室重构的不同影响。30只雄性SHR被随机分为三组:SHR-IR组(用厄贝沙坦治疗,50mg/kg),SHR-IM组(咪达普利,3mg/kg),SHR-C组(安慰剂)。10只接受安慰剂治疗的雄性Wistar Kyoto大鼠(WKY)作为对照。所有治疗从14至27周龄开始每日给药一次。咪达普利和厄贝沙坦对SHR的血压和左心室质量指数具有相似的抑制作用。尽管两种药物均抑制SHR中ERK-1蛋白表达,降低心肌细胞凋亡指数,阻止I型胶原沉积,减少TGF-β(1)基因表达,但咪达普利的抑制作用更强。厄贝沙坦对MKP-1蛋白表达影响不大,但咪达普利使其显著降低。结果,SHR-IR组中的ERK-1/MKP-1比值显著高于SHR-IM组(P<0.05)。这些结果表明,心肌组织中MKP-1和ERK之间的平衡对心脏细胞增殖和生长很重要。它们还表明,降压治疗在降低血压方面的相似疗效并不能预测其控制左心室重构各个方面的能力相似。厄贝沙坦在恢复ERK-1和MKP-1之间的稳态方面更有效,然而咪达普利在抑制心脏组织中的细胞凋亡和胶原合成方面更具优势。